Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on the day's biggest business stories
Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Sign up for Axios NW Arkansas
Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters
Photo: Rafael Henrique/SOPA Images/LightRocket via Getty Images
Peer-reviewed research published Tuesday confirms that the coronavirus vaccine developed by AstraZeneca and Oxford University is moderately effective at preventing infection, and it appears to keep people out of the hospital.
Why it matters: Some questions remain about AstraZeneca's vaccine, but the findings released in The Lancet medical journal help validate that the product works and is safe.
The big picture: When AstraZeneca's vaccine was administered in two standard doses, it was about 62% effective in preventing symptomatic infections.
- That's not as high as the roughly 95% efficacy reported by the Pfizer and Moderna vaccines, but AstraZeneca's has some other advantages over those two, including easier distribution.
- No one who had received both doses of the vaccine in AstraZeneca's trials developed a severe infection or had to be hospitalized.
The big question: The company accidentally gave some patients a modified dosing regimen — a half dose, followed by a full standard dose. In those patients, the vaccine registered 90% efficacy.
- Experts have puzzled over those results since AstraZeneca's initial release, and the research published Tuesday doesn't have many answers.
- The group that got the half-dose didn't include anyone older than 55 — the people most at risk for severe infection. We still don't know whether that skewed the results or AstraZeneca accidentally hit on a better dosage.
The lower initial dose also appeared to be much more effective in preventing asymptomatic spread — a critically important part of stopping the virus from spreading.